P02.12.B UNDERSTANDING THE ROLES OF EPHRIN A5 IN GLIOBLASTOMA AND ITS POTENTIAL AS A THERAPEUTIC TARGET

Abstract

Abstract BACKGROUND Glioblastoma (GBM) is the most common and aggressive malignant primary brain cancer and is associated with very poor patient outcomes. GBM has been classified into three cell subtypes (proneural (PN), classical (CL), and mesenchymal (MES)), which have been further defined into four plastic cell states (neural-progenitor-like (NPC-like), oligodendrocyte-progenitor-like (OPC-like), astrocyte-like (AC-like), and mesenchymal-like (MES-like)). Existing treatment options have had limited success in improving overall survival, with the extreme heterogeneity present in GBM presenting a major barrier to effective therapy. Thus, there is an urgent need to develop more effective therapeutic strategies which better capture heterogeneity and delay tumour relapse. Several erythropoietin-producing human hepatocellular (Eph) receptors and ephrin ligands have been shown to be functionally overexpressed in cancer and have become attractive therapeutic targets. EphA3 has previously been shown to be a functional, tumour-specific target, frequently elevated in the MES subtype. We identified ephrin A5, the high-affinity ligand of EphA3, to be frequently co-expressed with EphA3 in GBM tumours. However, unlike EphA3, the mechanisms of ephrin A5 in GBM remain understudied. We therefore believe that ephrin A5 serves as an attractive synergistic target for the treatment of GBM. MATERIAL AND METHODS We examined the expression of ephrin A5 in a panel of GBM patient specimens. A panel of GBM tumours were also selected for immunohistochemical and spatial transcriptomics analysis. For in vitro functional studies, ephrin A5 was overexpressed in several GBM primary cell lines. Assays examining proliferation, stemness and differentiation were performed. RESULTS Expression of ephrin A5 was comparable to EphA3 in GBM. 64% of GBM tumours analysed showed higher levels of ephrin A5, relative to the highest normal brain specimen. Initial immunohistochemistry analysis suggests EphA3 and ephrin A5 to be expressed discretely on over 75% of the total tumour mass. Spatial transcriptomics analysis suggests ephrin A5 to be enriched in cells of the AC-like cell state. In vitro overexpression of ephrin A5 was shown to reduce neurosphere formation and induce differentiation of GBM cells. CONCLUSION EphA3 and ephrin A5 are overexpressed in a portion of GBM tumours. Critically, there was a strong mutually exclusive expression to different compartments of the GBM tumour, covering the vast majority of the total tumour mass. Our data suggests that ephrin A5 overexpression drives a less aggressive, more differentiated AC-like tumour phenotype. Thus, dual targeting of EphA3 and ephrin A5 in GBM could provide an opportunity to better capture tumour heterogeneity and achieve more durable therapeutic responses.